The stock of Novabay Pharmaceuticals Inc (NBY) has seen a 15.91% increase in the past week, with a -14.01% drop in the past month, and a -47.79% decrease in the past quarter. The volatility ratio for the week is 10.82%, and the volatility levels for the past 30 days are at 12.02% for NBY. The simple moving average for the last 20 days is 4.36% for NBY’s stock, with a simple moving average of -72.49% for the last 200 days.
Is It Worth Investing in Novabay Pharmaceuticals Inc (AMEX: NBY) Right Now?
The stock has a 36-month beta value of 2.04. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NBY is 36.05M, and at present, short sellers hold a 0.58% of that float. On May 02, 2024, the average trading volume of NBY was 2.71M shares.
NBY) stock’s latest price update
Novabay Pharmaceuticals Inc (AMEX: NBY) has experienced a rise in its stock price by 10.89 compared to its previous closing price of 0.08. However, the company has seen a gain of 15.91% in its stock price over the last five trading days. Business Wire reported 2024-03-25 that EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers.
Analysts’ Opinion of NBY
Many brokerage firms have already submitted their reports for NBY stocks, with Ladenburg Thalmann repeating the rating for NBY by listing it as a “Buy.” The predicted price for NBY in the upcoming period, according to Ladenburg Thalmann is $1.10 based on the research report published on September 18, 2019 of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NBY reach a price target of $4. The rating they have provided for NBY stocks is “Buy” according to the report published on July 06th, 2018.
Laidlaw gave a rating of “Buy” to NBY, setting the target price at $8 in the report published on November 15th of the previous year.
NBY Trading at -23.80% from the 50-Day Moving Average
After a stumble in the market that brought NBY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.00% of loss for the given period.
Volatility was left at 12.02%, however, over the last 30 days, the volatility rate increased by 10.82%, as shares sank -14.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.29% lower at present.
During the last 5 trading sessions, NBY rose by +15.91%, which changed the moving average for the period of 200-days by -87.57% in comparison to the 20-day moving average, which settled at $0.0851. In addition, Novabay Pharmaceuticals Inc saw -56.08% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NBY
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.54 for the gross margin
The net margin for Novabay Pharmaceuticals Inc stands at -0.79. The total capital return value is set at -1.05. Equity return is now at value -139.03, with -75.81 for asset returns.
Based on Novabay Pharmaceuticals Inc (NBY), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -1.47.
Currently, EBITDA for the company is -4.8 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 0.19. The receivables turnover for the company is 19.39for trailing twelve months and the total asset turnover is 1.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
To sum up, Novabay Pharmaceuticals Inc (NBY) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
